Table 3. Factors associated with mortality using Cox proportional hazards model.
HR, hazard ratio; CI, confidence interval; HBV, hepatitis B; HCV, hepatitis C; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; cART, combination antiretroviral treatment. Bold type indicates significant covariates
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | PA | HR (95% CI) | P | PA | |
| Time dependent covariates | ||||||
| Current TCE statusB | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 2.10 (1.34–3.30) | 0.001 | 0.001 | 1.19 (0.75–1.88) | 0.454 | 0.454 |
| Current CD4 (cells µL−1)C | ||||||
| <200 | 1.00 | 1.00 | ||||
| 200–300 | 0.35 (0.18–0.68) | 0.002 | 0.37 (0.19–0.73) | 0.004 | ||
| 300–500 | 0.16 (0.09–0.29) | <0.001 | 0.19 (0.1–0.35) | <0.001 | ||
| 500+ | 0.09 (0.05–0.16) | <0.001 | <0.001 | 0.11 (0.06–0.2) | <0.001 | <0.001 |
| Current viral load (copies mL−1)C | ||||||
| ≤400 | 1.00 | 1.00 | ||||
| 400–10 000 | 1.34 (0.62–2.87) | 0.452 | 1.09 (0.50–2.39) | 0.819 | ||
| 10 000+ | 3.15 (1.97–5.03) | <0.001 | <0.001 | 1.84 (1.09–3.10) | 0.022 | 0.019 |
| Prior AIDSB | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 2.53 (1.64–3.9) | <0.001 | <0.001 | 1.52 (0.95–2.43) | 0.079 | 0.079 |
| Calendar year | ||||||
| 1997–2003 | 1.00 | |||||
| 2004+ | 0.92 (0.5–1.67) | 0.775 | 0.775 | |||
| Fixed covariates | ||||||
| Year started cARTC | ||||||
| 1997 | 1.00 | 1.00 | ||||
| 1998–99 | 0.91 (0.55–1.52) | 0.733 | 0.96 (0.58–1.62) | 0.895 | ||
| 2000+ | 1.62 (0.92–2.86) | 0.096 | 0.174 | 1.85 (1.03–3.33) | 0.039 | 0.079 |
| No. of drugs in first cART regimen | ||||||
| 3 | 1.00 | |||||
| ≥4 | 1.08 (0.44–2.68) | 0.859 | 0.859 | |||
| First cART regimen | ||||||
| NRTI ± PI, no NNRTI | 1.00 | |||||
| NNRTI + PI, ± NRTI | 1.50 (0.59–3.79) | 0.391 | ||||
| NRTI + NNRTI, no PI | 1.13 (0.74–1.74) | 0.568 | 0.642 | |||
| Exposure | ||||||
| Homosexual | 1.00 | |||||
| Other | 1.39 (0.88–2.18) | 0.154 | 0.324 | |||
| AgeC | ||||||
| <30 | 1.00 | 1.00 | ||||
| 30–39 | 1.35 (0.63–2.93) | 0.441 | 1.53 (0.70–3.32) | 0.284 | ||
| 40–49 | 1.29 (0.57–2.89) | 0.540 | 1.65 (0.72–3.75) | 0.229 | ||
| 50+ | 2.59 (1.17–5.75) | 0.019 | 0.012 | 3.73 (1.64–8.47) | 0.002 | 0.001 |
| Gender | ||||||
| Male | 1.00 | |||||
| Female | 0.72 (0.26–1.97) | 0.528 | 0.528 | |||
| Prior antiretroviral therapy | ||||||
| No | 1.00 | |||||
| Yes | 1.24 (0.81–1.91) | 0.324 | 0.324 | |||
| HBV statusC | ||||||
| Negative or not tested | 1.00 | 1.00 | ||||
| Positive | 2.82 (1.50–5.31) | 0.001 | 0.001 | 3.38 (1.76–6.50) | <0.001 | <0.001 |
| HCV statusB | ||||||
| Negative or not tested | 1.00 | 1.00 | ||||
| Positive | 1.9 (1.16–3.26) | 0.012 | 0.012 | 1.54 (0.89–2.65) | 0.120 | 0.120 |
A
P overall, P-values reported for test of homogeneity in nominal covariates and test for trend in ordinal covariates. Patients with missing data were not included for testing trend.
B
Variables included in the final model.
C
Covariates adjusted for the final model.